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Obesity plays a pivotal role in the development of low-grade inflammation. Dietary fatty acids are important
modulators of inflammatory responses. Saturated fatty acids (SFA) and n-6 polyunsaturated fatty acids (PUFA) have
been reported to exert pro-inflammatory effects. n-3 PUFA in particular, possess anti-inflammatory properties.
Numerous clinical studies have been conducted over decades to investigate the impact of dietary fatty acids on
inflammatory response in obese individuals, however the findings remained uncertain. High fat meals have been
reported to increase pro-inflammatory responses, however there is limited evidence to support the role of individual
dietary fatty acids in a postprandial state. Evidence in chronic studies is contradictory, the effects of individual dietary
fatty acids deserves further attention. Weight loss rather than n-3 PUFA supplementation may play a more prominent
role in alleviating low grade inflammation. In this context, the present review provides an update on the mechanistic
insight and the influence of dietary fats on low grade inflammation, based on clinical evidence from acute and chronic
clinical studies in obese and overweight individuals.
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Obesity is a global epidemic in both developed and de-
veloping countries. In the United States alone, it is esti-
mated that approximately 69% of adults are overweight
(BMI ≥25 kg/m2) and 36% are obese (BMI ≥30 kg/m2)
[1]. Obesity is associated with a cluster of metabolic syn-
drome, which is characterized by hyperglycemia, hyper-
tension, dyslipidemia, reduced high density lipoproteins
(HDL) cholesterol and abdominal obesity. Taken to-
gether, these metabolic disorders are closely linked to
chronic inflammation. Numerous studies have reported
that elevated adiposity is associated with increased plasma
pro-inflammatory cytokines [2-4].
Weight loss is known to improve obesity-associated
metabolic disorders, in particular low grade inflamma-
tion [5,6]. However, other dietary interventions aiming
at improving obesity-induced inflammation have not
been explored in detail. Long chain fatty acids are potent
inflammatory mediators [7]. In vivo and in vitro studies
have shown the pro-inflammatory effects of saturated* Correspondence: kt.teng@gmail.com
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reproduction in any medium, provided the orfats (SFA) [8-10] and polyunsaturated fats (PUFA), in
particular n-6 PUFA [11]. In contrast, n-3 PUFA, namely
docosahexaenoic acid (DHA) and eicosapentaenoic acid
(EPA) have anti-inflammatory properties [12-14]. Never-
theless, the evidence based on clinical studies in this re-
spect is limited and controversial. In this context, the
present review provides an update on the mechanistic as-
pects and the effect of dietary fats on low grade inflamma-
tion, based on clinical evidence from acute and chronic
clinical studies in obese and overweight individuals.Obesity-induced inflammation
Numerous studies found that compared to healthy lean in-
dividuals, overweight and obese individuals have higher
pro-inflammatory cytokines and lower anti-inflammatory
cytokines [15,16]. Obesity is characterized by having a
greater number of adipose tissue (hyperplasia) and an in-
crease in the size of adipocytes (hypertrophy) [17,18]. The
aforementioned conditions lead to oxygen depletion in
adipose tissue hence causing adipocyte cell death. In
addition, the excess storage of triacylglycerols (TAG) from
dietary intake results in an excessive influx of free fatty
acids into blood circulation. Taken together, this can leadd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Figure 1 TLR-4, toll-like-receptor 4; SFA, saturated fatty acids.
SFA stimulate inflammation through TLR-4 dependent and
independent pathways.
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duction of pro-inflammatory adipocytokines [19].
Adipocytes mediate inflammatory response by regulat-
ing the release of free fatty acids and adipocytokines, in
particular tumor necrosis factor-α (TNF-α), interleukin-
6 (IL-6), and monochemoattractant protein-1 (MCP-1)
[17,20]. MCP-1 stimulates the recruitment of macro-
phages into adipose tissue via MCP-1/CC chemokine
receptor 2 (CCR2) cascade [21,22]. The findings of macro-
phage infiltration in adipose tissue provide a mechanistic
insight into the obesity-induced low-grade inflammation.
This obesity-induced inflammatory state involves a pheno-
typic switch in adipose tissue macrophage from M2 to M1
state [23,24]. The detailed mechanism has been reviewed
[25]. In brief, instead of converting monocytes to M2 mac-
rophages, the migration of monocytes from the circulation
to the macrophage clusters surrounding dead adipocytes
switches M2 to the M1 state. M2 macrophages are also
known as alternatively activated macrophages, producing
anti-inflammatory cytokines such as interleukin-10 (IL-10)
and interleukin-1Ra (IL-1Ra) [17,22,23,25]. M1 macro-
phages are defined as classically activated macrophages,
and produce high concentrations of pro-inflammatory cy-
tokines i.e. TNF-α and IL-6. This phenotypic switch of M2
to M1 is characterized by a reduction in IL-10 and argi-
nase production, in conjunction with an increase in pro-
inflammatory TNF-α production [23,26].
Modulation of inflammation by dietary fatty
acids: mechanistic insights
Saturated fatty acids
Numerous in vitro and in vivo studies have shed light on
the inflammatory effect of SFA [27-29]. Evidence from a
substantial number of studies has reported that SFA
stimulate inflammatory response by a pathway involving
Toll-like receptors (TLR) (Figure 1). TLR are a class of
pattern recognition receptors that play a crucial role in
an innate immune system (reviewed in [30]). Elevated
levels of TLR-4 have been reported in the obese state
whereby the expression was found in many insulin target
tissues such as liver, muscle, brain, adipose tissue, vascu-
lature and pancreatic β-cells [31]. The absence of TLR in
studies on mice demonstrated the diminished effect of
insulin resistance modulated by pro-inflammatory path-
ways [32,33].
SFA is the acyl component of lipopolysaccharides (LPS),
which is a ligand of TLR-4. It was reported that glycopro-
teins e.g. myeloid differentiation protein 2 (MD2) and a
cluster of differentiation 14 (CD14) are needed for the
binding of SFA to TLR-4 [34]. It has also been suggested
that there are two pathways involved in the SFA-mediated
inflammatory mechanisms, namely TLR-4-dependent and
TLR-4-independent pathways (reviewed in [25]). SFA have
been reported to induce TLR-4-dependent gene expressionby promoting dimerization of TLR-4, a necessary step
in receptor activation, within specialized lipid domains
termed “lipid rafts” in macrophages [35]. The stimula-
tory effects of SFA, lauric, palmitic and stearic acids in
particular, have been found to increase IL-6 gene ex-
pression in macrophage via the TLR-4 dependent path-
way [36]. In line with this, stearic acid has also been
found to stimulate the release of MCP-1 expression via
TLR-4 [37]. TLR-4 activates pro-inflammatory pathways
by stimulating the expression of transcription factors,
including IKKβ and NF-κB [31,32].
Other than the TLR-dependent pathway, SFA stimulate
pro-inflammatory mechanisms through the TLR-indepen
dent pathway by producing reactive oxygen species (ROS).
ROS activate nucleotide-binding domain, leucine-rich
repeat containing family, pyrin domain-containing 3
(NLRP3) inflammasome [38] that forms a complex with
apoptotic speck protein (ASC), known as NLRP3- ASC
inflammasome complex [39]. This complex regulates the
cleavage of interleukin-1β (IL-1β) from pro-IL-1β [40,41].
The release of IL-1β decreases insulin signalling in insulin
target cells, providing a possible SFA-mediated inflamma-
tory response leading to insulin resistance [42,43].
Polyunsaturated fatty acids
n-6 PUFA, also known as linoleic acid (LA) is thought to
be pro-inflammatory and it can be converted into ara-
chidonic acid (AA) [44]. AA is the major substrate for
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in regulating inflammatory and immune responses [45].
Eicosanoids consist of prostaglandins, prostacyclins, throm-
boxanes, and leukotrienes. Biosynthesis of eicosanoid
products are regulated by three major enzymes, namely
cyclooxygenases, lipoxygenases and cytochrome P450s
[46]. Most of the AA-derived eicosanoid products are
pro-inflammatory, except prostaglandins E2 (PGE2) and
lipoxins which have anti-inflammatory effects [47,48].
n-3 PUFA, namely linolenic acid (ALA) is known to ex-
hibit anti-inflammatory properties [12,14,49]. Deep sea fish
like salmon and mackerel are sources of n-3 PUFA. n-3
PUFA can be converted into EPA and DHA [44]. A number
of reviews have been reported on the anti-inflammatory
mechanisms of n-3 PUFA (Figure 2) [26,45,50]. One of the
anti-inflammatory effects of n-3 PUFA is the downregula-
tion of pro-inflammatory cytokines in adipose tissue such
as TNF-α, IL-6 and MCP-1, which can be explained by
several possible pathways [34,50-53]. The first possible
pathway is the binding of EPA and DHA with the G
protein-coupled receptor 120 (GPR120) [54]. Activated
GPR120 internalizes as plasma membrane with β-
arrestin2 to form GPR120/ β-arrestin2 complex. The
complex which then associates with TAB1, results in the
inhibition of TAK1 and prevents the downstream sig-
nalling to NF-κB and JNK systems [53].Figure 2 Dotted line, inhibit; solid line, activate. EPA, eicosapentaenoic
120; JNK, JUN NH2-terminal kinase; TLR-4, toll-like-receptor 4; NF-κB, nuclear fa
arachidonic acid; PGE2, prostaglandins E2. Anti-inflammatory mechanisms of E
GPR120. Incorporation of these n-3 PUFA disrupts the translocation of TLR
DHA interfere with the TLR-4 signaling pathway via the downregulation o
pathway. These fatty acids also activate PPARγ and, result in the upregula
and DHA leads to antagonism of n-6 fatty acid arachidonic acid (AA).While SFA were found to stimulate TLR-4 signalling,
EPA and DHA were found to inhibit the TLR-4 signal-
ling pathway [34]. The TLR-4 signalling pathway may be
blocked by DHA and EPA through the downregulation
of nicotinamide adenine dinucleotide phosphase-oxidase
(NADPH oxidase) production [50]. NADPH oxidase in-
duces ROS production, which is found to be necessary
for TLR-4 signalling [51]. In addition, the incorporation
of DHA into lipid membrane disrupts the translocation
of TLR-4 into lipid raft, thus inhibiting the TLR-4 signal-
ling pathway [50,55]. The disrupted TLR-4 signalling
pathways lead to the inhibition of NF-κB thus resulting in
the downregulation of inflammatory responses [53,54].
These findings indicate that the intake of EPA and DHA
reduces the secretion of pro-inflammatory cytokines, and
it may also be possible that these n-3 PUFA play a role in
preventing macrophage infiltration into adipose tissue
[50]. Findings from human [49,56] and rodent [57] studies
reported that the production of adiponectin increases with
a higher intake of EPA and DHA. However, the upregu-
lation of adiponectin secretion may be associated with
peroxisome proliferator- activated receptor γ (PPARγ)
activation [57,58]. The upregulation of leptin by DHA is
found to have a similar pathway with adiponectin [50].
It was suggested that a diet rich in EPA and DHA re-
sults in a higher incorporation of these fatty acids intoacid; DHA, docosahexaenoic acid; GPR120, G protein-coupled receptor
ctor kappa-β; PPARγ, peroxisome proliferator-activated receptor γ; AA,
PA and DHA. EPA and DHA inhibit NF-κB and JNK through binding with
-4 into lipid raft, thus inactivates NF-κB pathway. Besides, EPA and
f NADPH oxidase production, which results in the inhibition of NF-κB
tion of adiponectin and leptin secretion. In addition, the intake of EPA
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higher intake of EPA and DHA may reduce the produc-
tion of AA-derived eicosanoid products, thereby providing
another n-3 PUFA induced anti-inflammatory effect [47].
Clinical evidence
Numerous prospective epidemiological studies have re-
ported association between dietary fats and low grade in-
flammation. However, it is noteworthy that the effect
may be speculative based on the association between
changes in plasma fatty acids and levels of inflammatory
cytokines. Clinical evidence provides a direct measure-
ment of the impact of dietary intake on circulating
inflammatory markers. Hence in the present review,
clinical studies were identified by searching Pubmed,
EMBASE, Cochrane databases. Inclusion criteria were
English language articles reporting the measurement of
at least one inflammatory marker including cytokines,
vascular adhesion molecules, C-reactive proteins (CRP)
in both postprandial and fasting measurements following
the ingestion of high fat meals or dietary intervention
(3-week and above) in overweight and obese individuals
(BMI ≥ 25 kg/m2 or waist circumference > 80 cm for
women and >90 cm for men) for the last 10 years. Stud-
ies investigating subjects under 18 y, lean and healthy,
taking antioxidant supplements, pregnant and lactating,
having chronic inflammatory related diseases were ex-
cluded. A total of 9 papers on acute studies and 12 pa-
pers on chronic studies were included in the following
discussion.
Acute dietary intake
Amount of dietary fats on postprandial inflammatory
response
Postprandial lipemia provokes the release of pro-inflam
matory markers and impairs insulin response. A repetitive
exposure of endothelial cells to pro-inflammatory cyto-
kines leads to the progression of chronic diseases such
as diabetes and cardiovascular diseases [59,60]. Previ-
ous studies found that postprandial inflammation is
augmented in obese and overweight individuals as cyto-
kines are secreted by adipose tissue [16,61]. The quantity
of fat is thought to have greater impact on postprandial in-
flammatory response in overweight and obese than in
healthy lean individuals [15]. This hypothesis is supported
by a recent study which reported that the consumption of
a high fat mixed meal increased plasma IL-6 and hsCRP
concentrations compared with water (control) in 10 obese
males [62] (Table 1). The mixed meal consisted of 57.5 g
dietary fat (with 29 g saturated fat) derived from bacon,
egg muffin, 2 hash browns with a glass of caramel-
flavored milk drink. The mixed meal however did not
alter plasma TNF-α and adiponectin concentrations and
the similar observations were reported after the waterintake. Manning et al. [16] however reported that both
low and high fat meals increased plasma IL-6 concen-
trations but had no effect on plasma TNF-α and IL-8
concentrations in 15 obese women. The low fat meals
were mashed potato (12 g fat) or all bran (13 g fat),
whereas high fat meals were 200 g instant mashed po-
tato enriched with cream (high SFA, 71 g), olive oil
(high monounsaturated fats (MUFA), 72 g) or canola oil
(high PUFA, 72 g). The low and high fat meals were not
iso-caloric and the obese women ingested fats in pro-
portion with their body weight. These conflicting find-
ings may be explained by the differences in study
design; (1) gender (men vs. women), (2) control used
(water vs. 12 g fat), (3) amount of fat in high fat meals
(57.5 g vs. 0.6 g/kg in proportion with body weight,
which is equivalent to 72 g total fat), (4) composition of
mixed meals and (5) measurement time point.
The discrepancies observed in these two studies may
further be explained by a study conducted by Blackburn
et al. [63]. A relatively larger sample size with 38 obese
men ingested a high fat mixed meal consisted of eggs,
cheese, toast, peanut butter, whipped cream, peaches
and milk. The total fat was given at 60 g/m2 body sur-
face area. This has resulted in an increase in plasma IL-6
concentrations but TNF-α and hsCRP concentrations
remained unchanged. Miglio et al. [64] however observed
an increase in postprandial plasma TNF-α concentrations
following the ingestion of 82 g high fat mixed meal. In the
study, 15 overweight men and women ingested a high
fat mixed meal consisted of fried potatoes, fried eggs,
Emmenthal cheese, and Italian rose-shaped dinner rolls,
served with 500 ml low sugar content beverage. These dis-
crepant of findings could be attributed to the different
time point of blood sampling. The results observed by
Blackburn et al. [63] at 4 h after meal commencement
may have prevented the notice of an early increase in
plasma TNF-α concentrations, as observed by Miglio et al.
[64] at 1 h after meals. Amount of fat used by Miglio et al.
[64] was higher compared to other studies [16,62,63], but
a previous study reported that the ingestion of meals
enriched with 50 g of fats enabled the detection of post-
prandial changes in plasma IL-6 and TNF-α concentrations
in healthy subjects [65]. This suggests that the studies
discussed have incorporated sufficient amount of fats to
detect the postprandial changes in plasma cytokines.
The activation of NF-kB has been reported to regulate
the release of cytokines during postprandial period [66].
Patel et al. [15] reported that a high fat, high carbohydrate
meal increased the ROS generation and NF-κB binding ac-
tivities in 8 obese subjects (3 men and 5 women). In the
study, subjects consumed a high fat mixed meal consisted
of a Big Mac, a large French fries, a large Coke and an
apple pie, providing approximately 60 g of fats. However,
the postprandial duration was relatively short (3 h) and
Table 1 Acute effects of the amount of dietary fats on inflammatory response in obese or overweight individuals










0, 1, 2, 3, 4, 5,
6 h
HFM: 57.5 g fat (29 g SFA)
A bacon and egg muffin, 2 hash browns,
caramel flavored milk drink (250 ml of 4%
fat milk, 4 teaspoons skim milk powder
and 1 teaspoon caramel flavor)




HFM ↑ over time; NS
HMW adiponectin: =; NS
Sample size was calculated
based on the changes of
adiponectin, but not other
markers
[62]
Water (control) Small sample size
Lean: 14 (14/-);
obese: 15 (15/-)
0, 1, 4, 6 h SFA: 71 g fat (18 g palmitate)
Instant potato with 16 g cream/kg body
weight, 100 ml hot water
IL-6: ↓ at 1 h, ↑ at 6 h; NS
IL-8, TNF-α: =; NS
Timing of menstrual cycle
and oral contraceptive usage
were not taken into account
[16]
MUFA: 72 g fat (9 g palmitate )
Instant potato with 0.6 g/kg body weight
of olive oil, 160 ml hot water
Subjects with hypertension
and dyslipidemia were included
n-6 PUFA:72 g fat (5 g palmitate)
Instant potato with 0.6 g/kg body weight
of canola oil, 160 ml hot water
Test meals were not iso-caloric
Small sample size.
LFM–potato: 12 g fat (3 g palmitate)
Instant potato, 160 ml hot water.
LFM – bran: 13 g fat (3 g palmitate)
All-Bran, 40 ml trim milk, and 2 cooked eggs
*test meals for obese subjects only
Obese: 38 (−/38) 0, 4, 8 h 60 g fat/m2 body surface
Eggs, cheese, toast, peanut 7, whipped
cream, peaches and milk
IL-6: ↑ at 6 h
TNF-α: ↓ at 4 h
Control not included [63]
Overweight:
15 (2/13)
0, 0.5, 1, 2, 4, 6,
8 h
82 g fat (36.9 g SFA)
Fried potatoes, fried eggs, Emmenthal
cheese, Italian rose-shaped dinner rolls,
with 500 ml of low sugar content beverage








0, 1, 2, 3 h HFM, 60 g fat
Big Mac, large French fries, a large Coke,
and apple pie
ROS generation and






HFM, high fat meal; LFM, low fat meal; SFA, saturated fats; MUFA, monounsaturated fats; PUFA, polyunsaturated fats; % en, percentage energy; IL, interleukin;
hsCRP, high-sensitivity C-reactive protein; TNF-α, tumor necrosis factor- alpha; sICAM-1, soluble intracellular adhesion molecule-1; sVCAM-1, soluble vascular adhesion
molecule-1; HMW, high molecular weight; AUC, area under the curve; ROS, reactive oxygen species; NF-κB, nuclear factor kappa-β; ↓, reduced postprandial
concentrations; ↑, increased postprandial concentrations; =, no postprandial/after meal effect; ↑↑, higher postprandial increment compared to other meals; NS,
no significant difference between meals.
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measured; hence the relation between NF-κB and the re-
lease of cytokines deserves further investigation. Taken to-
gether the evidence available, the consumption of high fat
meals may lead to the increase of postprandial inflamma-
tory markers, in particular plasma IL-6, as well as the ROS
generation and NF-κB binding activities in overweight and
obese individuals.
Type of dietary fats on postprandial inflammatory
response
Masson and Mensink [67] reported that in 13 over-
weight men, plasma IL-6, TNF-α and soluble vascular
adhesion molecule-1 (sVCAM-1) concentrations de-
creased after n-6 PUFA meal, while the markers were in-
creased after SFA meal (Table 2). The subjects wererandomly assigned to high fat meal enriched with 50 g
butter (SFA meal), or 40 g margarine plus 10 g safflower
oil (n-6 PUFA meal). Both test meals were served in the
form of muffins (two per subject) with a glass of water
(250 ml). Interestingly, decreased plasma MCP-1 con-
centrations were observed after both high fat meals,
while no meal effect was reported for plasma IL-8 and
soluble intracellular adhesion molecule-1 (sICAM-1)
concentrations. In contrast, Manning et al. [16] observed
that all high fat meals regardless of type of fats increased
plasma IL-6 concentrations in a similar manner but had
no impact on plasma IL-8 and TNF-α concentrations in
15 obese women. The inconsistencies of results reported
by these two studies may be explained by the gender dif-
ferences (men vs. women) of the subjects as discussed
earlier. Furthermore, the differing content of linoleic












0, 15, 30, 45,
60, 90 min, 2,
3, 4, 5, 6, 7, 8 h
SFA: 56.6 g fat (33.9 g SFA)
2 muffins with butter and 250 ml
water
IL-6, TNF-α, sVCAM-
1: SFA ↑, PUFA ↓
MCP-1: ↓ over time;
NS sICAM-1: = ; NS
Small sample size [67]
n-6 PUFA: 60.5 g fat (12.9 g SFA, 21.8 g PUFA)
2 muffins with 40 g butter and 10 g margarine,
and 250 ml water
A low fat lunch was served after 3 h
Lean: 14 (14/-)
Obese: 15 (15/-)
0, 1, 4, 6 h SFA: 71 g fat (18 g palmitate)
Instant potato with 16 g cream/kg body weight,
100 ml hot water
IL-6: ↓ at 1 h, ↑
at 6 h; NS
IL-8, TNF-α: =; NS
Timing of menstrual cycle
and oral contraceptive
usage were not taken into
account
[16]
MUFA: 72 g fat (9 g palmitate)
Instant potato with 0.6 g/kg body weight of olive




n-6 PUFA:72 g fat (5 g palmitate ) Instant
potato with 0.6 g/kg body weight of canola oil,
160 ml hot water
Test meals were not iso-
caloric
Small sample size
LFM–potato: 12 g fat (3 g palmitate)
Instant potato, 160 ml hot water.
LFM – bran: 13 g fat (3 g palmitate)
All-Bran, 40 ml trim milk, and 2 cooked eggs
*test meals for obese subjects only
Lean: 18 (−/18)
Obese: 18 (−/18)
0, 2, 4 h SFA: 95 g fat (51 g SFA)
Shakes containing low fat yogurt, low fat milk,
strawberry flavor, sugar and 95 g palm oil
IL-8: ↑ over time; NS






MUFA: 95 g fat (8 g SFA)
Shakes containing low fat yogurt, low fat milk,
strawberry flavor, sugar and 95 g high oleic
sunflower oil
n-3 PUFA: 95 g fat (32 g SFA)
Shakes containing low fat yogurt, low fat milk,
strawberry flavor, sugar and 40 g palm oil + 55 g





0, 2, 4 h SFA: 95 g fat (51 g SFA)
Shakes containing low fat yogurt, low fat milk,




IL-8: MUFA and n-3





MUFA: 95 g fat (8 g SFA)
Shakes containing low fat yogurt, low fat milk,
strawberry flavor, sugar and 95 g high oleic
sunflower oil
n-3 PUFA: 95 g fat (32 g SFA)
Shakes containing low fat yogurt, low fat milk,
strawberry flavor, sugar and 40 g palm oil + 55 g




0, 1, 2, 4, 6 h SFA: 83 g fat
Refined palm oil blended with 1% milk,
strawberry flavored syrup, low fat frozen, and
non-fat dry milk powder.
CRP: ↑; over time NS
TNF-α: ↓ over time; NS
NF-κB AUC (4 h):
PUFA ↑↑, SFA↑
VCAM-1: =; NS
ICAM-1: =; MUFA ↓↓
vs. SFA, n-3 PUFA
Small sample size
Test meals were not iso-
caloric
[71]
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Table 2 Acute effects of the type of dietary fats on inflammatory response in obese or overweight individuals
(Continued)
MUFA: 83 g fat
Refined olive oil blended with 1% milk, strawberry
flavored syrup, low fat frozen, and non-fat dry
milk powder.
n-3 PUFA: 85 g fat
Refined olive oil + 4 g n-3FA from 8 g fish oil
supplement pills (300 mg EPA, 200 mg DHA/g),
blended with 1% milk, strawberry flavored syrup,
low fat frozen, and non-fat dry milk powder.
LFM, low fat meal; SFA, saturated fats; MUFA, monounsaturated fats; PUFA, polyunsaturated fats; % en, percentage energy; IL, interleukin; hsCRP, high-sensitivity C-
reactive protein; TNF-α, tumor necrosis factor- alpha; sICAM-1, soluble intracellular adhesion molecule-1; sVCAM-1, soluble vascular adhesion molecule-1; TAG, triac-
ylglycerols; MCP-1, monochemoattractant protein-1; PBMC, peripheral blood mononuclear cells AUC, area under the curve; ↓, reduced postprandial concentrations;
↑, increased postprandial concentrations; =, no postprandial/after meal effect; ↑↑, higher postprandial increment compared to other meals; NS, no significant differ-
ence between meals.
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to the discrepant findings. Evidence from in vitro find-
ings suggested a pro-inflammatory effect of n-6 PUFA,
however the effect is uncertain in human studies [68]. In
addition, the sources of SFA (butter vs. cream) used may
attribute to the diversifying results. Butter contains sub-
stantial amount of medium chain triglycerides which
may be better absorbed compared with cream with dif-
ferent physical characteristics [69].
The following three studies reported that n-3 PUFA
had no favorable impact on the postprandial responses
of plasma cytokines when compared with MUFA or SFA
rich oils. Esser et al. [61] provided 18 obese men SFA
(95 g palm oil), MUFA (95 g high oleic sunflower oil), or
n-3 PUFA (40 g palm oil plus 55 g Marinol D-40)
enriched shakes. The study reported that the high fat
meals increased plasma IL-8 concentrations, and re-
duced plasma IL-6 concentrations in a similar magni-
tude but no impact on plasma CRP concentrations.
Another similar study by Van Dijk et al. [70] reported
null effects on plasma IL-1β and TNF-α concentrations
in obese men, irrespective of the type of fats consumed
(refined palm oil as SFA, refined olive oil as MUFA, and
refined olive oil plus 4 g of n-3FA from 8 g fish oil sup-
plement pills as n-3PUFA). The study however, observed
lower peripheral blood mononuclear cells (PBMC)
MCP-1 and IL-8 concentrations after SFA compared
with MUFA and n-3 PUFA high fat meals in obese men.
This observation concurs with an earlier study in 10
obese overweight subjects [71]. Although the postpran-
dial effect on plasma cytokines (CRP, TNF-α, sICAM-1
and sVCAM-1) did not vary, n-3 PUFA was found to
activate NF-κB expression compared with SFA. The
authors explained that the lower activation of NF-κB by
SFA may be attributed to the palmitate content in the
palm oil, as in vitro studies have shown that high levels
of palmitate may suppress NF-κB activation [27]. Des-
pite the diminished effect on plasma cytokines, the
activation of NF-κB may suggest that the synthesis andsecretion processes of plasma cytokines may not occur
concurrently in the cell and extracellular tissue, hence sug-
gesting that a complex pathophysiological mechanism
involved.
Evidence to-date suggests that there is no clear benefi-
cial effect of the consumption of PUFA rich meals on
postprandial plasma inflammatory cytokines. On the
other hand, SFA rich meals may not be detrimental in
an acute feeding scenario in obese and overweight indi-
viduals. However, high fat meal may promote elevated
postprandial inflammatory response, with limited evidence
on varying cytokines. It is also important to understand
that the repetitive exposure of dietary fatty acids on the
whole body homeostasis may only be observed in long-
term dietary intervention studies.
Chronic dietary intervention
Effects of the type of dietary fats on inflammation
n-6 PUFA (particularly of linoleic acid), is negatively
viewed as pro-inflammatory considering the fact that it
can be metabolized into AA and subsequent undesirable
metabolites. Furthermore, n-6 PUFA may compete for
cyclooxygenase thus reducing the formation of anti-
inflammatory mediators from n-3 PUFA [72]. Never-
theless, a rigorously well conducted systematic review
reported that no clinical evidence to-date were able to
suggest the pro-inflammatory effects of linoleic acid in
healthy, noninfant individuals [73]. However these find-
ings may need further confirmation in overweight and
obese individuals. The baseline levels of inflammatory
markers in lean healthy individuals are appreciably lower
compared to an overweight population. Hence the im-
pact of dietary fatty acids may virtually be negligible in
lean healthy population. Two recent studies in obese in-
dividuals however have reported discrepant findings
(Table 3). Kralova Lesna et al. [74] conducted a 3-week
dietary intervention with predominant PUFA (25% en
PUFA from vegetable oils) or SFA (29% en SFA from
animal fat content) in 14 overweight, dyslipidemic and
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tively high intake of PUFA decreased plasma CRP com-
pared with baseline but no comparison was made
between diets. The small sample size and short study
duration with limited statistical interpretation may reduce
the strength of findings. In addition, Bjermo et al. (2012)
reported that n-6 PUFA decreased plasma IL-1RA and
TNF-R2 concentrations compared with a SFA-enriched
diet after a 10-week iso-caloric dietary intervention in 61
abdominally obese individuals [75]. n-6 PUFA (from sun-
flower oil) was exchanged at 10% en with SFA derived pre-
dominantly from butter. The well powered study with
longer duration may explain the positive findings of n-6
PUFA. However, the results generated may be less convin-
cing based on the high noncompliance reported (PUFA,
16%; SFA, 34%). Furthermore, it is to be noted that the
non-equally distributed participants (16-31%) on antihy-
pertensive and lipid-lowering drugs, may confound the
levels of circulating cytokines in a parallel study [76,77].
The anti-inflammatory effects of n-3 PUFA has been
confirmed in prospective epidemiological and in vitro
findings. Thus, the anti-inflammatory potential of n-3
PUFA has been put to a rigorous test in clinical trials.
However, five studies reported conflicting findings.
Maki et al. [78]reported that supplementation of krill oil
(216 mg EPA, 90 mg DHA), menhaden oil (212 mg
DHA, 178 mg EPA) or control (2 g olive oil) for 4-week
to 25 overweight individuals did not alter plasma CRP.
In contrary, Kiecolt-Glaser et al. (2012) reported that
the consumption of two doses of n-3 PUFA (1.25 vs
2.5 g/day, EPA: DHA ratio is 7:1) for 4 months in 46 ab-
dominally overweight individuals resulted in discernable
reduction in plasma TNF-α and IL-6 concentrations
[79]. It is plausible that the longer duration with suffi-
ciently powered design enable the detection of positive
findings. Furthermore, ideal balance of EPA to DHA
may play a critical role as evidence suggests that EPA
may be more anti-inflammatory than DHA [80,81]. In
agreement with Kiecolt-Glaser et al. [79], a recent study
found that 55 severely obese nondiabetic patients pro-
vided with 3.36 g n-3 PUFA (EPA, DHA) for 8-week ex-
perienced a marked decrease in plasma IL-6 but not
hsCRP concentrations [82]. Interestingly, the study also
reported that n-3 PUFA decreased the expression of
varying inflammatory genes in subcutaneous adipose
tissue and increased the production of eicosanoids in
both visceral and subcutaneous adipose tissue com-
pared with butter fat (control). The beneficial effect of
n-3 PUFA was evident in severely obese patients (BMI ≥
40 kg/m2) and this again proven that the impact of diet-
ary fats on plasma cytokines is attributed to the baseline
levels of circulating cytokines.
To investigate the plant-based n-3 PUFA, namely ALA,
Nelson et al. [83] fed healthy abdominally overweightindividuals with flaxseed oil (5% en ALA of total energy
intake or 11 g/day, n = 27) or habitual diet (n = 24), in a
parallel design for 8-week. The targeted fat exchange with
ALA was achieved at 10 g/day or 4.6% en of total fat in-
take as reported by self-reporting dietary record. No sig-
nificant changes was observed for plasma IL-6, TNF-α and
CRP concentrations. However, measurable increase of
EPA and DHA was detected in erythrocyte cell mem-
branes suggesting the conversion of ALA to EPA and
DHA in the relatively short study duration. The primary
differences between this study and previously reported
were the fat source (plant-based ALA), younger age (~ 38
y), and relatively healthy overweight individuals. This fur-
ther supports the hypothesis that the baseline levels of cy-
tokines were too low for any discernable changes. Taken
together, the effect of dietary fats, in particular n-6
PUFA required further confirmation. The beneficial
effects of n-3 PUFA may only be observed in severely
obese individuals with higher baseline levels of plasma
cytokines. Further studies bridging the gap of informa-
tion are needed.
Restricted calorie diets with varying amount of dietary
fats on inflammation
Weight loss lowers the risk for developing cardiovascular
diseases, but sustained weight loss is difficult to achieve.
In this context, dietary approach is needed. The effect of
restricted diets with varying amount of dietary fats on low
grade inflammation is uncertain. Sharman and Volek [84]
conducted a 6-week crossover dietary intervention with
reduced energy diets (low fat vs very low carbohydrate
(VLCKD), ~1500 kcal) in 15 overweight men (Table 4). A
low level of ketosis was ascertained as an indication of
compliance. Plasma TNF-α, IL-6, hsCRP and sICAM-1
concentrations did not differ between diets but appre-
ciably reduced compared with baseline. Forsythe et al. [85]
conducted a parallel study with longer period dietary
intervention (12-week) in a group of overweight individ-
uals with dyslipidemia. Similar weight reduction was
achieved in a longer period of time as compared with
Sharman and Voleks [84]. The study reported that both
diets significantly decreased concentrations of several
pro-inflammatory cytokines but profound alterations
were observed after VLCKD intervention as evident by
remarkable decrease in an array of markers (TNF-α,
IL-6, IL-8, MCP-1, E-selectin, sICAM and plasminogen
activator inhibitor-1 (PAI-1)). The authors suggested
that the lower inflammatory response in VLCKD may
be correlated with the increased plasma n-6 PUFA
levels attributed by a higher saturated fat intake. How-
ever, the higher weight loss achieved by VLCKD group
may also contribute to a more remarkable improvement
in inflammatory status.
Table 3 Chronic effects of the type of dietary fats on low grade inflammation in obese or overweight individuals








40% en total fat (25% en PUFA,
8.5% en SFA)
Fat from vegetable sources
CRP: PUFA↓ vs baseline







42% en total fat (29% en SFA,
3% en PUFA)




Iso-caloric diet (2738 kcal) with ~21%
en exchange between PUFA and SFA
Abdominally overweight:
61 (gender not specified)




40% en total fat (10% en SFA,
13.5% en LA)
Scones (baked using sunflower oil),











40% en total fat (20% en SFA,
4% en LA)
Scones (baked using butter), butter
and butter
Low compliance: n-6 PUFA
diet (n = 27); SFA diet (n = 19)
Iso-caloric diet (2000 kcal) consisted
with 10% en exchange between n-6









Krill oil: 90 mg DHA + 216 mg EPA
Menhaden oil: 178 mg DHA +
212 mg EPA
Control: 2 g olive oil
4 x 500 mg capsules/day for each
supplementation








n-3 PUFA: 2.5 g/dayFish oil
(6 x 500 mg capsules/d);EPA:DHA
ratio is 7:1
TNF-α, IL-6: both doses ↓
vs placebo; NS
Calorie and fatty acid
composition of habitual
diets were not standardized
[79]
n-3 PUFA 2.5 g/day:
46 (29/17)
n-3 PUFA: 1.25 g/day:
46 (28/18)
Placebo: 46 (36/10)
n-3 PUFA: 1.25 g/day
Placebo: 3 g
Mixture of palm, olive, soy, canola
and cocoa butter oils; (SFA:MUFA:
PUFA ratio = 37:42:21)
Severely obese:
55 (46/9)




n-3 PUFA: 4 x 1 g capsules/day
(3.36 g EPA + DHA)
Control: 5 g butterfat








Iso-caloric diet consisted of 30%
en fat, 15% protein and 55%
en carbohydrate
SAT gene expression of
CCL2, CCL3, H1F1A and
TGFB1: n-3 PUFA ↓
EPA- and DHA-derived
eicosanoids synthesis in






ALA: 11 g/day flaxseed oil
Control: habitual diet
IL-6, TNF-α, CRP: NS [83]
ALA: 27 (21/6)
Control: 24 (19/5)
Iso-caloric diet (~2000 kcal) with a
balance of SFA and MUFA intake
% en, percentage energy; IL-1RA, interleukin-1 receptor antagonist; TNF-R2, tumor necrosis factor- receptor 2; hsCRP, high-sensitivity C-reactive protein; IL,
interleukin; TNF-α, tumor necrosis factor- alpha; ALA, alpha linolenic acid; SFA, saturated fats; MUFA, monounsaturated fats; PUFA, polyunsaturated fats; DHA,
docosahexaenoic acid; EPA, eicosapentaenoic acid; VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue; CCL, chemokine (C-C) motif ligand; HIF1A,
hypoxia-inducible factor 1-alpha; TGFB1, transforming growth factor β1; NS, no significant difference between diets; ↓, reduced concentrations; ↑, increased concentrations.
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VLCKD 60% en total fat, 10% en CHO, 30% en protein
Unlimited type of fat or cholesterol amount
from sources such as beef, poultry, fish, oils, various
nuts/seeds, moderate amount of vegetables, salads
with low-carbohydrate dressings, moderate amount
of cheese, eggs, protein powder, water/ low-carbohydrate
diet drinks, low-carbohydrate bars and shakes
*Customied diabetic exchange lists were used.
TNF-α, IL-6, hsCRP, sICAM-1: both
VLCKD & LFD ↓ vs baseline: NS
sP-sel: NS






LFD 25% en fat, 55% en CHO, 20% en protein




60% en fat 10% en CHO 30% en protein
Unlimited amount of beef, poultry, fish, eggs, oils
and heavy creams; moderate amount of hard
cheeses, low-carbohydrate vegetables and salad
dressings; small amount of nuts, nut butters
and seeds.
TNF-α, IL-8, MCP-1, E-selectin,
sICAM-1 PAI-1: both VLCKD &
LFD ↓ vs baseline; VLKCD ↓↓
IL-6, CRP, VEGF, P-sel, EGF and










25% en fat, 55% en CHO, 20% en protein (< 10%
SFA, < 300 mg cholesterol)
Whole grains (bread, cereals and pastas), fruit/fruit
juices, vegetables, vegetables oils, low at dairy, and
lean meat products
*Standard diabetic exchange lists were used.
Body weight: VLCKD ↓ 5.6 kg,
LFD ↓3.7 kg
VLCKD, very low carbohydrate ketogenic diet; LFD, low fat diet; CHO, carbohydrate; % en, percentage energy; SFA, saturated fats; TNF-α, tumor necrosis factor- alpha; IL,
interleukin; hsCRP, high-sensitivity C-reactive protein; sICAM-1, soluble intracellular adhesion molecule-1; sP-sel, soluble P-selectin; MCP-1, monochemoattractant
protein-1; PAI-1, plasminogen activator inhibitor-1; VEGF, vascular endothelial growth factor; EGF, epidermal growth factor; sVCAM-1,soluble vascular adhesion molecule-1;
NS, no significant difference between diets; ↓, reduced concentrations; ↓↓, greater reduction compared to the other diets.
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on inflammation
In recent years, the effect of n-3 PUFA on weight loss
has been studied extensively. Four studies have been
identified in this respect (Table 5). Munro and Garg [86]
reported that a low energy diet combined with n-3
PUFA (8% en of total fat intake, 0.42 g EPA + 1.62 g
DHA from fish oil) or control (MUFA, sunola oil) for
12-week did not differ on plasma adiponectin, leptin,
hsCRP and IL-6 concentrations. A significant weight loss
was achieved and a 2-fold increase in plasma EPA and
DHA suggested compliance. Nevertheless, Kratz et al.
[87] provided 16 women and 10 men a diet rich in n-3
PUFA (3.5% en of total fat intake, from both plant and
marine sources) or a control diet (3.2% en intake from
MUFA) for a consecutive 2-week lead-in followed by a
2-week iso-caloric period and a 12-week ad libitum
period. Weight loss resulted in an expected increase
in adiponectin levels during the ad libitum period. Both
n-3 PUFA and control diets however did not alter
plasma adiponectin levels. The authors discussed that
the dose of fish oil provided (725 mg) is equivalent to
the amount of 125-250 g fatty fish/day, which is on the
higher end of human consumption.
Two similar studies were conducted to compare the
effects of n-3 PUFA (1.1 g/day n-3 PUFA with 0.6 gEPA, 0.5 g DHA) and MUFA (control, high oleic sun-
flower oil) supplementation vs weight loss on inflamma-
tory biomarkers in 11 healthy moderately obese men
[5,6]. The subjects consumed a succession of very low
calorie diet for 4-week, followed by a 2-week restricted
calorie diet and a 2-week weight sustained diet. At the
end of dietary intervention, fasting blood samples were
collected followed by a 4 h postprandial high fat chal-
lenge (50 g fat with 2:2:1 ratio of SFA:MUFA:PUFA).
Weight loss (~9.4 kg) reduced both fasting and post-
prandial sICAM, hsCRP and postprandial IL-6, sTNF-
R55, sTNF-R75 and PAI-1 antigen. MCP-1 was lowered
by both n-3 PUFA and weight loss. Hence, weight loss
rather than n-3 PUFA supplementation had prominent
impact on low grade inflammation.
Strengths and limitations
The current evidence provides insight on the influence
of amount and type of dietary fats on inflammatory re-
sponse in both acute and chronic dietary intervention
studies in obese and overweight individuals. The present
review is not a systematic review with grading tools ap-
plied, however the limited evidence in hand suggests
that dietary fats may play a pivotal role in modulating
low grade inflammation in a potentially vulnerable group
of population to disease progression. However, the









Parallel: 12-week n-3 PUFA: 6 capsules of 1 g fish oil daily
(0.42 g EPA + 1.62 g DHA/d)
Body weight: n-3 PUFA











Daily intake were 5000 kJ for female and
6000 kJ for males with ~30% en total fat
intake




Parallel: 14-week Phase 1 (lead-in):
34.3% en fat (4.8% en n-6, 0.5% en n-3
PUFA)
Body weight after Phase 3:










Both n-3 PUFA and control groups
consumed the same diet
Phase 2 (iso-caloric, 1800 kcal)):
n-3 PUFA: 12 capsules of 725 mg fish oil
(2.88 g n-3 PUFA)
34.7% en fat (n-6 PUFA, 4.9% en, n-3
PUFA, 3.6% en)
Main source of n-3 PUFAs: canola and
flaxseed oils, and margarines rich in ALA
Adiponectin: both
diets ↑ vs baseline; NS
HMW adiponectin: NS
Control: high oleic sunflower oil capsules
34.3% en total fat (4.8% en n-6, 0.5% en
n-3 PUFA)
Main source of oils: high oleic safflower
and sunflower oils, and margarines based
on these oils
Phase 3 (ad libitum):
115% of the amount of food provided in










(very low calorie diet, 4-week;
restricted energy diet, 2-week;
weight sustained diet, 2-week)
Phase 1 (fish oil study):
n-3 PUFA: 0.6 g EPA + 0.5 g DHA
Control: 6 capsules 500 mg of high
oleic sunflower oil with ad-libitum
Dutch diet









Phase 2 (weight loss period):
Very low calorie diet: 480 kcal/day
with shakes + 250 g vegetables and
fruits except banana
Postprandial challenges at the
end of each intervention: 0, 2, 4 h
Restricted energy diet: 1000 kcal/day
with mixed solid energy-restricted diet
with a recommended composition
Weight sustained diet: Diet at
commensurate calories to maintain
the newly achieved weights
Postprandial meals: 50.1 g fat, milkshake
Obese:
11 (−/11)
Cross-over Phase 1 (fish oil study):
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Phase 2: 8-week (very low calorie
diet, 4-week; restricted energy diet,
2-week; weight sustained diet,
2-week)
Control: 6 capsules 500 mg of
high oleic sunflower oil
with ad-libitum Dutch diet
No fish consumption is allowed
Postprandial sICAM,
hsCRP: weight loss ↓
MCP1: PUFA & weight
loss ↓
sel: NS
Phase 2 (weight loss period):
Very low calorie diet: 480 kcal/day
with shakes + 250 g vegetables and
fruits except banana
Postprandial challenges at the
end of each intervention: 0, 2, 4 h
Restricted energy diet: 1000 kcal/day
with mixed solid energy-restricted diet
with a recommended composition
Weight sustained diet: Diet at
commensurate calories to maintain
the newly achieved weights
Postprandial meals: 50.1g fat, milkshake
% en, percentage energy; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; HMW, high molecular weight; MUFA, monounsaturated fats; PUFA, polyunsaturated
fats; hsCRP, high-sensitivity C-reactive protein; IL, interleukin; PAI-1, plasminogen activator inhibitor-1; sTNF-R55, soluble tumor necrosis factor receptor 55; sTNF-R75,
soluble tumor necrosis factor receptor 75; sICAM-1, soluble intracellular adhesion molecule-1; sE-sel, soluble E-selectin; MCP-1, monochemoattractant protein-1; NS, no
significant difference between diets; ↓, reduced concentrations; ↑, increased concentrations.
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need for better designed dietary intervention in order to
unravel the crucial role of fatty acids on low grade in-
flammation. Most of the studies reported are underpow-
ered hence reflecting variations which may mask the
true effects of dietary treatment. In addition, the com-
parisons made were based on dietary fats as a whole ra-
ther than a head-to-head comparison of individual fatty
acid per se. The results generated thus may not be ex-
trapolated to individual fatty acid. In addition, the source
of dietary fats whether from animal or vegetable origin
may generate remarkable varying findings. This is in par-
ticular obvious when palm oil was used as SFA instead
of butter or cream as discussed. The physical character-
istics such as solid fat content or melting point have
been reported to produce discernable outcome on post-
prandial lipemia [88]. Furthermore, population difference
is another concern to be noted. The subjects recruited
ranging from healthy overweight to severely obese with
mildly elevated dyslipidemia, young to elder women to
men may generate differing outcome. For acute studies in
particular, the minimum amount of fat required to induce
a remarkable postprandial inflammatory response is 50 g
[65]. The composition of test meals i.e. mixed meal vs milk
shake may generate differing outcome which may compli-
cate data interpretation. The selection of control meal
may also affect the results generated. Furthermore, proper
blood sampling time point and procedure may greatly in-
fluence the detection of postprandial changes. Collective
information has suggested that lower plasma IL-6 levels
were observed at 1 hour after high fat meals, the missing
time point may lead to different outcome [63,64].Furthermore, diverting observation was obtained when
different methods of blood sampling were used. It was
reported that cannula rather than indwelling catheter
causes minimal changes in plasma IL-6 [89]. However
this may not be practical for study involving multiple
blood samplings. The existing data on chronic studies
highlights the need for proper designed studies. Most
of the previous studies reported information on the in-
take of dietary fat using self-reporting dietary records.
The major pitfall of dietary recall is the underestima-
tion of dietary intake and lack of validation of method-
ology used [90]. In addition, the duration of dietary
intervention in order to detect significant changes and
dosage applied may also lead to inconsistency of find-
ings. Taken together, future studies addressing these
issues may provide more reliable and conclusive
evidence on the role of dietary fatty acids on low grade
inflammation.
Conclusion
High fat meal may provoke inflammatory response in a
postprandial state however the effect of type of dietary
fats remained uncertain. Dietary fats, in particular n-3
PUFA may play a pivotal role in improving inflammatory
status in severely obese individuals, however the impact
may be marginal compared with weight loss. No conclu-
sive evidence on the effect of type of dietary fatty acids
on varying cytokines. A complete understanding on the
role of dietary fatty acids on low grade inflammation
merits further investigation. Information is needed based
on rigorously well designed clinical studies.
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